Pfizer Settles 10,000 Zantac Lawsuits Alleging Cancer Link

NEW YORK - JANUARY 26: A Pfizer sign hangs on the outside of their headquarters after a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion creating the world's largest biopharmaceutical company. (Photo by Mario Tama/Getty Images)
(Photo by Mario Tama/Getty Images)

OAN’s James Meyers
1:32 PM – Wednesday, May 8, 2024

Pfizer has agreed to financially settle 10,000 lawsuits which allege that the pharmaceutical company did not disclose to patients that possible cancer risks were associated with its anti-heartburn medication Zantac.


This also comes after Texas Attorney General Ken Paxton sued Pfizer “for unlawfully misrepresenting the effectiveness of the company’s COVID-19 vaccine and attempting to censor public discussion of the product” in 2023.

The Zantac lawsuits were filed in state courts across the U.S., but the agreements do not completely resolve Pfizer’s exposure to the claims linking Zantac to cancer, according to Bloomberg News

Terms of the settlements were not disclosed. 

Zantac was introduced into the market in 1983 by Glaxo Holdings, a company that is now part of the GlaxoSmithKline company. In 1988, it was the world’s best selling drug of its kind as patients reported benefits for conditions such as acid reflux, heartburn, and ulcers. 

By 1997, Glaxo’s patent for Zantac’s active ingredient, ranitidine, expired. 

In the same year, pharmaceutical companies also started working on generic versions of the drug. 

However, in 2020, the Food and Drug Administration (FDA) asked drugmakers to pull Zantac and its generic versions of the drug after a cancer-causing compound called NDMA was found in samples.

As a result, thousands of lawsuits began coming in federal and state courts against GSK, Pfizer, Sanofi, and Boehringer Ingelheim. 

In April, Sanofi reached an agreement in principle to settle 4,000 lawsuits linking Zantac to cancer. Although Sanofi did not disclose the official financial terms of the deal, Bloomberg News reported that the company will pay around $100 million, or $25,000 to each plaintiff. 

Meanwhile, a Chicago woman named Angela Valadez, 89, who claimed to have contracted colon cancer after taking Zantac for over 20 years, filed a lawsuit recently and it went to trial last week. She filed the suit against GSK and Boehringer Ingelheim.

Stay informed! Receive breaking news blasts directly to your inbox for free. Subscribe here.

Share this post!